Arquivos do dia: Outubro 13, 2021
OMS recomenda a aplicação da 3ª dose da vacina contra COVID em grupos de mais alto risco.
13 Out, 2021 | 13:43hWHO advisers recommend 3rd COVID vaccine dose for highest-risk groups – CIDRAP
Ver também: WHO advises additional COVID shot for immunocompromised people – Reuters
Opinião | Lição da COVID: confie no público com verdades concretas.
13 Out, 2021 | 13:42hCOVID lesson: trust the public with hard truths – Nature
Comentário do autor no Twitter (fio – clique para saber mais)
Today in @Nature, I outline a key lesson from COVID-19:
"Governments, dare to to trust your citizens."
Governments' fear of their people is not supported by science & it stymies pandemic management and breeds vaccine hesitancy.
Read it here: https://t.co/dbr5Epggow.
🧵 (1/8) pic.twitter.com/EegEIxGb2r
— Michael Bang Petersen (@M_B_Petersen) October 12, 2021
Uma cartilha sobre o que se sabe a respeito de misturar e combinar vacinas contra Covid.
13 Out, 2021 | 13:40hA primer on what we know about mixing and matching Covid vaccines – STAT
Conteúdos relacionados:
Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.
RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.
Dados de vida real mostram que filtros eliminam do ar o vírus causador da COVID.
13 Out, 2021 | 13:39hReal-world data show that filters clean COVID-causing virus from air – Nature
Artigo original: The removal of airborne SARS-CoV-2 and other microbial bioaerosols by air filtration on COVID-19 surge units – medRxiv
Comentário no Twitter
Research at a hospital swamped by people with COVID-19 has confirmed that portable air filters effectively remove SARS-CoV-2 particles from the air https://t.co/OT3JKIxWhB
— nature (@Nature) October 11, 2021
Soroconversão e febre são fatores dose-dependentes em um modelo primata não humano de COVID-19 inalatória.
13 Out, 2021 | 13:37hComentário: Dose-dependent COVID-19 symptoms – Nature Reviews Microbiology
Comentários no Twitter
When exposed to #SARSCoV2 why does one person have no illness, while another is soon in ICU?
Dose.
Controlled study in monkeys shows the dose of viruses inhaled is a key factor determining the severity of the disease.
Seems obvious, yet this is new.https://t.co/zdfCnR40bR pic.twitter.com/HH8kxMM2xm— Laurie Garrett (@Laurie_Garrett) October 11, 2021
In summer of 2020, our group had proposed a hypothesis that SARS-CoV-2 viral dose or "inoculum" was associated with severity of symptoms in COVID (and proposed NPIs reduced the dose). There is now an experimental model showing this in cynomolgus monkeys:https://t.co/dXGDPyPBFZ
— Monica Gandhi MD, MPH (@MonicaGandhi9) October 12, 2021
M-A | Frequência de manifestações neurológicas na COVID-19: até 1/3 dos pacientes (89% internados) vivenciaram pelo menos 1 manifestação neurológica.
13 Out, 2021 | 13:36hDiretriz preliminar da USPSTF revisa a diretriz anterior e agora recomenda contra iniciar aspirina em baixa dose como prevenção primária de doença cardiovascular (DCV) em pessoas com 60 anos de idade ou mais.
13 Out, 2021 | 13:25hComentários:
Advice shifting on aspirin use for preventing heart attacks – Associated Press
Taking aspirin to prevent heart attack may cause more harm than good, task force says – NPR
Estudos randomizados relacionados:
Randomized Trial: Aspirin for Primary Prevention of Cardiovascular Disease
Randomized Trial: Effects of Aspirin for Primary Prevention in Persons with Diabetes
Randomized Trial: Effect of Aspirin on All-Cause Mortality in the Healthy Elderly
Metanálises relacionadas:
Meta-Analysis: Efficacy and Safety of Aspirin for Primary Prevention of Cardiovascular Events
Opiniões relacionadas:
Aspirin for Primary Prevention: Is This the End of the Road?
Evidence evolving on aspirin as prevention – ACP Internist
Comentário no Twitter
Low Dose Aspirin in the Primary Prevention of Cardiovascular Disease: #USPSTF recommends individualized decision making between 50 and 59 years, and against aspirin use in 60 years+. What a difference a few years can make, with more data and evidence. https://t.co/3nC3jpjTDq pic.twitter.com/SN8K3Z9XJj
— Muin J. Khoury (@MuinJKhoury) October 12, 2021
Diretriz de consenso | Tratamento da hiperpotassemia no departamento de emergência.
13 Out, 2021 | 13:23hConteúdo relacionado: Review: Clinical Management of Hyperkalemia. Classification and monitoring, when to reinitiate RAASi therapy, use oral K+-binding agents, and more
Podcast: Hyperkalemia, Diet, K+ Binders, Exercise
Hyperkalemia: Pathophysiology, Risk Factors and Consequence
Hyperkalemia: Pathophysiology, Risk Factors and Consequence (vários artigos)
ACR anuncia novos critérios de adequação para exames diagnósticos.
13 Out, 2021 | 13:21hAmerican College of Radiology Announces New Appropriateness Criteria – Medical Device News Magazine
Nova diretriz: ACR Appropriateness Criteria
Estudo randomizado | Tratamento com laser não é melhor que tratamento simulado quanto à gravidade dos sintomas vaginais pós-menopausa.
13 Out, 2021 | 13:19hEffect of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal Symptoms: A Randomized Clinical Trial – JAMA (gratuito por tempo limitado)
Comunicado de imprensa: This laser is supposed to rejuvenate vaginal tissue. But scientists say it’s no better than a placebo – University of New South Wales
Editorial: Time for a “Pause” on the Use of Vaginal Laser (free for a limited period)
Entrevista com os autores: Effect of Carbon Dioxide Laser vs Sham Therapy on Women With Postmenopausal Vaginal Symptoms
Comentário: Vagina lasering for postmenopausal women ‘may be placebo’ – The Guardian
Comentário no Twitter
In a randomized clinical trial among women with postmenopausal vaginal symptoms, treatment with fractional carbon dioxide laser vs sham treatment did not improve vaginal symptoms after 12 months https://t.co/XXv5edTLiL
— JAMA (@JAMA_current) October 12, 2021